DeForest McDuff, Ph.D.

 

Education

  • Ph.D., Economics, Princeton University
  • M.A., Economics, Princeton University.
  • B.A., Economics, University of Maryland, College Park, summa cum laude
  • B.S., Mathematics, University of Maryland, College Park, summa cum laude

Professional Experience

  • Insight Economics, LLC (www.insighteconomics.com). Co-Founder and Partner. Boston MA. 2017 to present.
  • Academic Integrity Seminar, LLC (www.integrityseminar.org). Boston MA. Co-Founder and Partner. 2006 to present.
  • Intensity Corporation (formerly Quant Economics). San Diego CA and Boston MA. Economist from 2009 to 2012, Senior Economist from 2012 to 2013, Vice President from 2013 to 2017, Head of Boston Office from 2015 to 2017
  • JPMorgan Chase & Co. New York NY. Trading Analyst, 2006 to 2007.
  • Princeton University. Princeton NJ. Economic Research Assistant, 2004 to 2006.
  • Academic Referee. Review of Economics and Statistics; Journal of Urban Economics; Economics of Education Review; Journal of Housing Economics; Journal of Real Estate Economics and Finance.

Professional Memberships

  • American Economics Association (AEA).
  • Licensing Executives Society (LES).

Publications and Papers

    McDuff, DeForest, Gary Pavela, and Donald McCabe: “Updated: Ten Principles of Academic Integrity for Faculty,” (2017) AIS Newsletter.
    McDuff, DeForest, Ryan Andrews, and Matthew Brundage: “Thinking Economically About Commercial Success,” (2017) Landslide, Volume 9, Number 4, 37-40.
    McDuff, DeForest: “Splitting the Atom: Economic Methodologies for Profit Sharing in Reasonable Royalty Analysis,” (2016) les Nouvelles June 2016, 70-73.
    McDuff, DeForest and Daryl Fairweather: “Measuring Marketing: Using Content Analysis to Evaluate Relative Value in Valuation and Reasonable Royalty Analysis,” (2016) les Nouvelles. June 2016, 88-93.
    McDuff, DeForest, Ryan Sullivan, and Justin Skinner: “Downgrade to ‘Neutral’: A Diminishing Role of the Georgia-Pacific Factors in Reasonable Royalty Analyses,” (2015) les Nouvelles 50(3), 134-137. Licensing Executives Society Article of the Month: March 2016.
    McDuff, DeForest and Ryan Sullivan: “AstraZeneca and Damages In ‘At-Risk’ Generic Drug Launches,” April 28, 2015, Law360.
    McDuff, DeForest and Justin Skinner: “Reasonable Royalties: All About that Base … Or That Rate,” December 18, 2014, Law360.
    McDuff, DeForest, Susan McDuff, Jennifer Farace, Carolyn Kelley, Maria Sovoia, and Jess Mandel: “Evaluating a Grading Change at UCSD School of Medicine: Pass/Fail Grading is Associated with Decreased Performance on Preclinical Exams but Unchanged Performance on USMLE Step 1 Scores” (2014) BioMed Central Medical Education 14:127.
    McDuff, DeForest and Justin Skinner: “Apple v. Motorola May Help Defenders of Daubert Challenges” with Justin Skinner, May 21, 2014, Law360.
    McDuff, DeForest: “Home Price Risk, Local Market Shocks, and Index Hedging,” (2012) The Journal of Real Estate Finance and Economics 45(1), 212–237.
    McDuff, DeForest: “Demand Substitution Across U.S. Cities: Observable Similarity and Home Price Correlation,” (2011) Journal of Urban Economics 70(1), 1–14.
    McDuff, DeForest: “Quality, Tuition, and Applications to In-State Public Colleges,” (2007) Economics of Education Review 26(4), 433–449.
    McDuff, DeForest: “Analyzing Income and Happiness: The Effects of Placing Too Much Emphasis on Income in a Job” (2005), Princeton manuscript.

Speaking Engagements

    “Price Optimization in E-Commerce,” Presenter, Global Big Data Conference, Boston MA, 2016.
    “Damages Whirlwind: Navigating Reasonable Royalties in 2015,” Presenter, Boston Patent Law Association, Boston MA, 2015.
    “Asset Valuation and Patent Monetization: A Review of Valuation Methods and Transaction Structures,” Presenter, Law Seminars International, San Francisco CA, 2015.
    “Jury Trials for At-Risk Generic Launches,” Presenter, Continuing Legal Education, Los Angeles CA, 2015.
    “Careers for PhDs in Start-ups,” Panelist, University of California at San Diego, San Diego CA, 2014.
    “How to Prove Reasonable Royalty in Patent Damages,” Panelist, The Knowledge Congress, San Diego CA, 2013.
    “Careers in Economics and Finance,” Presenter, University of California at San Diego, San Diego CA, 2010.
    “Home Price Risk, Local Market Shocks, and Index Hedging,” Presenter, National Bureau of Economic Research, Boston MA, 2008.

Awards

    National Science Foundation Graduate Research Fellowship. Awarded to top 25 graduate students in economics nationwide each year, Princeton University.
    Princeton University Graduate Research Fellowship. Full tuition fellowship and stipend for graduate research, Princeton University.
    Towbes Teaching Prize for Outstanding Teaching. Awarded to top 4 teaching assistants in the economics department each semester, Princeton University.
    Dillard Prize. Awarded to top undergraduate in economics, University of Maryland.

Expert Testimony and Consulting

    1. Merck Sharp & Dohme Corp., Cubist Pharmaceuticals LLC, Optimer Pharmaceuticals LlcLLC MSD Investment Holdings (Ireland), and MSD International GMBH v. Actavis Laboratories Fl, Inc., Actavis Pharma, Inc., and Actavis Inc. United States District Court of New Jersey, Case No. 2:15-cv-06541-WHW-CLW. Expert report. Evaluation of commercial success of Dificid (fidaxomicin) for the treatment of Clostridium difficile-associated diarrhea.
    2. Gilead Sciences, Inc. v. Mylan Pharmaceuticals Inc. United States District Court of Delaware, Case No. 16-cv-00192-RGA. Expert report and deposition. Evaluation of commercial success related to Tybost, Evotaz, Prezcobix, Stribild, and Genvoya for the treatment of HIV.
    3. Immunex Corporation, Amgen Manufacturing, Limited, and Hoffmann-LA Roche Inc., v. Sandoz Inc., Sandoz International GMBH, and Sandoz GMBH. United States District Court of New Jersey, Case No. 2:16-cv-01118-CCC-MF. Expert reports (x2). Evaluation of indications for and commercial success of Enbrel (etanercept) for the treatment of rheumatoid arthritis, psoriasis, and other indications.
    4. United Therapeutics Corporation and Supernus Pharmaceuticals, Inc., v. Actavis Laboratories FL, Inc. United States District Court of New Jersey, Case No. 3:16-cv-01816-PGS-PHG. Expert report. Evaluation of commercial success related to Orenitram (treprostinil) for the treatment of pulmonary arterial hypertension.
    5. Cipla Ltd. v. Sunovion Pharmaceuticals Inc., United States District Court of Delaware, Case No. 15-cv-00424-LPS. Expert reports (x2) and deposition. Evaluation of patent infringement including reasonable royalty related to Xopenex HFA (levalbuterol tartrate) for the treatment of bronchospasm.
    6. Cave Consulting Group, Inc. v. Truven Health Analytics Inc., United States District Court of Northern California, San Francisco Division, Case No. 3:15-cv-02117-SI. Expert report. Evaluation of patent infringement including reasonable royalty related to healthcare analytics software products.
    7. In the Inter Partes Review of U.S. Patent 9,358,240, United States Patent and Trademark Office, Patent Trial and Appeal Board, IPR2017-10621; In the Inter Partes Review of U.S. Patent 9,339,507, United States Patent and Trademark Office, Patent Trial and Appeal Board, IPR2017-10622. Expert declarations (x2). Evaluation of commercial success related to Tyvaso (treprostinil) for the treatment of pulmonary arterial hypertension.
    8. United Therapeutics Corporation v. Watson Laboratories, Inc. United States District Court of New Jersey, Case No. 3:15-cv-05723. Expert report and deposition. Evaluation of commercial success related to Tyvaso (treprostinil) for the treatment of pulmonary arterial hypertension.
    9. In the Inter Partes Review of U.S. Patent 6,881,745. United States Patent and Trademark Office, Patent Trial and Appeal Board, IPR2016-01186. Expert declaration and deposition. Evaluation of commercial success related to Noxafil (posaconazole) for the treatment of fungal infections.
    10. Sanofi-Aventis U.S. LLC, Aventis Pharma S.A. and Sanofi v. Fresenius Kabi USA, LLC, Accord Healthcare, Inc., BPI Labs, LLC, Belcher Pharmaceuticals, LLC, Apotex Corp., Apotex, Inc., Breckenridge Pharmaceutical, Inc., Mylan Laboratories Ltd., Actavis LLC, Dr. Reddy’s Laboratories, Inc., Dr. Reddy’s Laboratories, Ltd., Glenmark Pharmaceuticals, Inc., USA, and Glenmark Pharmaceuticals Ltd. United States District Court, District of New Jersey, Case Nos. 3:14-cv-07869; 3:14-cv-08082; 3:15-cv-02631; 3:14-cv-08079; 3:15-cv-02520; 3:14-cv-08081; 3:15-cv-02521; 3:15-cv-00287; 3:15-cv-01835; 3:15-cv-00289; 3:15-cv-01836; 3:15-cv-00290; 3:15-cv-03392; 3:15-cv-00776; 3:15-cv-03107; 3:15-cv-02522; and 3:15-cv-02523. Expert report, deposition, and trial testimony. Evaluation of commercial success related to Jevtana (cabazitaxel) for the treatment of prostate cancer.
    11. Carucel Investments, L.P. v. Novatel Wireless, Inc., AT&T Mobility, LLC, and Verizon Communications, Inc. United States District Court, Southern District of California, Case No. 3:16-cv-00118. Expert reports (x2), deposition, and trial. Evaluation of patent infringement including reasonable royalty related to telecommunications for MiFi devices.
    12. Vivus, Inc. v. Actavis Laboratories, FL, Inc. United States District Court, District of New Jersey, Case No. 2:14-cv-03786; Vivus, Inc. v. Dr. Reddy’s Laboratories, S.A., and Dr. Reddy’s Laboratories, Inc., United States District Court, District of New Jersey, Case No. 2:15-cv-02693-SRC-CLW. Expert reports (x2) and deposition. Evaluation of commercial success related to Qsymia (phentermine and topiramate) for the treatment of obesity.
    13. ABC Distributing, Inc., Elite Wholesale, Inc., Tonic Wholesale, Inc. dba Ace Wholesale v. Living Essentials, LLC and Innovation Ventures, LLC. United States District Court, Central District of California, Case No. 1:14-cv-00395. Expert reports (x2) and depositions (x2). Evaluation of class action restitution and antitrust damages related to price discrimination for Five-Hour Energy.
    14. Gilead Sciences, Inc. and Royalty Pharma Collection Trust v. Watson Laboratories, Inc. and SigmaPharm Laboratories, LLC. United States District Court, District of New Jersey, Case No. 1:15-cv-02350. Expert report and deposition. Evaluation of commercial success related to Letairis (ambrisentan) for the treatment of pulmonary arterial hypertension.
    15. In the Inter Partes Review of U.S. Patent RE38,551 E1. United States Patent and Trademark Office, Patent Trial and Appeal Board, IPR2016-00204. Expert declaration and deposition. Evaluation of commercial success related to Vimpat (lacosamide) for the treatment of epilepsy.
    16. GlaxoSmithKline LLC, SmithKline Beecham (Cork) Limited v. Glenmark Pharmaceutical Inc., USA. United States District Court, District of Delaware, Case No. 1:14-cv-00877. Expert reports (x2) and deposition. Evaluation of patent infringement including lost profits, reasonable royalty, and commercial success related to Coreg (carvedilol) for the treatment of congestive heart failure.
    17. In the Inter Partes Review of U.S. Patent RE44,186. United States Patent and Trademark Office, Patent Trial and Appeal Board, IPR2015-01340. Expert declaration and deposition. Evaluation of commercial success related to Onglyza (saxagliptin) and Kombiglyze (saxagliptin and metformin HCI extended-release) for the treatment of type 2 diabetes.
    18. Pfizer Inc., Wyeth LLC, Pfizer Pharmaceuticals LLC, PF Prism C.V., and Pfizer Manufacturing Holdings LLC v. Mylan Laboratories Limited. United States District Court, District of Delaware, Case No. 1:15-cv-00026. Expert report and deposition. Evaluation of commercial success related to Tygacil (tigecycline) for the treatment of infections.
    19. Pfizer Inc., and UCB Pharma GmBH v. Mylan Pharmaceuticals, Inc. United States District Court, District of Delaware, Case No. 1:15-cv-00079. Expert reports (x2), deposition, and trial testimony. Evaluation of commercial success related to Toviaz (fesoterodine) for the treatment of overactive bladder.
    20. DNA Genotek, Inc. v. Spectrum Solutions LLC and Spectrum DNA. United States District Court, Southern District of California, Case No. 3:16-cv-01544. Expert declaration and deposition. Evaluation of economic harm related to genetic testing kits.
    21. Acorda Therapeutics, Inc. and Alkermes Pharma Ireland Limited v. Aurobindo Pharma USA Inc., Alkem Laboratories Ltd., Roxane Laboratories, Inc., Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA Inc., Apotex Corp., and Apotex Inc. United States District Court, District of Delaware, Case No. 1:14-cv-00882 (consolidated). Expert report, deposition, and trial. Evaluation of commercial success related to Ampyra (4-aminopyridine) for the treatment of multiple sclerosis.
    22. Eli Lilly and Company, Eli Lilly Exports S.A., and Acrux DDS Pty Ltd. v. Watson Laboratories, Inc., Actavis, Inc., and Actavis Pharma, Inc. United States District Court, Southern District of Indiana, Case No. 1:13-cv-01799. Expert reports (x2). Evaluation of irreparable harm related to Axiron (testosterone) for the treatment of male hypogonadism.
    23. Art Cohen (individually and on behalf of all others similarly situated) v. Donald J. Trump. United States District Court, Southern District of California, Case No. 3:13-cv-02519. Expert report and deposition. Evaluation of class action damages related to RICO allegations related for alleged misrepresentations regarding Trump University.
    24. Orexo AB and Orexo US, Inc. v. Actavis Elizabeth LLC. United States District Court, District of Delaware, Case No. 1:14-cv-00829. Expert report and deposition. Evaluation of commercial success related to Zubsolv (buprenorphine and naloxone) for the treatment of opioid dependence.
    25. In the Inter Partes Review of U.S. Patent Nos. 6,858,650; 7,384,980; 7,855,230; 7,985,772; and 8,338,478. United States Patent and Trademark Office, Patent Trial and Appeal Board, IPR2016-00510; IPR2016-06136; IPR2016-01665; and IPR2016-01596. Expert declaration. Evaluation of commercial success related to Toviaz (fesoterodine) for the treatment of overactive bladder.
    26. Sanofi and Sanofi-Aventis U.S., LLC v. Glenmark Generics Inc., USA, Glenmark Pharmaceuticals Limited, Watson Laboratories Inc., Alkem Laboratories Ltd., First Time US Generics LLC, Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Alembic Pharmaceuticals Limited, and Sandoz Inc. United States District Court, District of Delaware, Case No. 1:14-cv-00264. Expert report, deposition and trial. Evaluation of commercial success related to Multaq (dronedarone) for the treatment of atrial fibrillation.
    27. NCR Corporation v. Documotion Research, Inc. United States District Court, District of Delaware, Case No. 1:14-cv-00395. Expert report and deposition. Evaluation of patent infringement including lost profits and reasonable royalty for food and beverage labeling products.
    28. In the Inter Partes Review of U.S. Patent No. 8,822,438. United States Patent and Trademark Office, Patent Trial and Appeal Board, IPR2016-00286. Expert declarations (x2) and deposition (x2). Evaluation of commercial success related to Zytiga (abiraterone) and the treatment of prostate cancer.
    29. CH2O, Inc. v. Meras Engineering, Inc., Houweling’s Nurseries Oxnard, Inc., HNL Holdings, Ltd., Houweling Utah Operations, Inc., and Houweling’s Nurseries, Ltd. United States District Court, Central District of California, Case No. 2:13-cv-08418. Expert report, deposition, declaration, and trial. Evaluation of patent infringement including lost profits and reasonable royalty for patent infringement related to agricultural technology.
    30. TrendSettah USA Inc. and Trend Settah, Inc. v. Swisher International, Inc. United States District Court, Central District of California, Case No. 8:14-cv-01664. Expert report, declaration, deposition, and trial. Evaluation of antitrust liability and damages, including evaluation of market definition, market power, monopolization, and damages related to tobacco products.
    31. Lights Out Holdings, LLC and Shawne Merriman v. Nike, Inc. United States District Court, Southern District of California, Case No. 3:14-cv-00872. Expert report and deposition. Evaluation of trademark infringement and false endorsement related to athletic apparel.
    32. Enzo Life Sciences, Inc. v. Abbott Laboratories and Abbott Molecular, Inc. United States District Court, District of Delaware, Case No. 1:12-cv-00274. Expert reports (x4) and deposition. Evaluation of patent infringement including economic prejudice and reasonable royalties related to molecular diagnostics.
    33. Merck Sharp & Dohme B.V. v. Warner Chilcott Company, LLC and Warner Chilcott (US), LLC. United States District Court, District of Delaware, Case No. 1:13-cv-02088. Expert report, deposition, and trial. Evaluation of commercial success related to NuvaRing (estonogestrel/ethinyl estradiol) and contraception products.
    34. DNA Genotek, Inc. v. Spectrum DNA, Spectrum Solutions, LLC, and Spectrum Packaging, LLC. United States District Court, District of Delaware, Case No. 1:15-cv-00661. Expert declaration and deposition. Evaluation of patent infringement including economic harm related to genetic testing kits.
    35. Eisai Co., Ltd., and Novartis Pharma AG v. Glenmark Pharmaceuticals Ltd., Glenmark Generics Ltd., Glenmark Generics Inc., USA, Hetero Labs LTD., Hetro USA, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., and Roxane Laboratories, Inc. United States District Court, District of Delaware, Case Nos. 13-1279-LPS; 13-1280-LPS; 13-1281-LPS; 13-1282-LPS; 13-1284-LPS. Expert report and deposition. Evaluation of commercial success related to Banzel (rufinamide) for the treatment of epilepsy.
    36. UCB, Inc., UCB Biopharma SPRL, Research Corporation Technologies, Inc., and Harris FRC Corporation v. Accord Healthcare, Inc., Intas Pharmaceuticals, Ltd., Alembic Pharmaceuticals, Ltd., Alembic Pharma Limited, Amneal Pharmaceuticals, LLC, Amneal Pharmaceuticals of New York, LLC, Apotex Corp., Apotex, Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., Vennoot Pharmaceuticals, LLC, Hetero USA, Inc., Hetero Labs Limited, Mylan Pharmaceuticals, Inc., Mylan, Inc., Sandoz, Inc., Sun Pharma Global FZE, Sun Pharmaceuticals Industries Ltd., Watson Laboratories, Inc.-Florida, Watson Pharma, Inc., Actavis, Inc., Zydus Pharmaceuticals (USA), Inc., and Cadila Healthcare Ltd. dba Zydus Cadila. United States District Court, District of Delaware, Case No. 1:13-cv-01206. Expert report, deposition, and trial. Evaluation of commercial success related to Vimpat (lacosamide) for the treatment of epilepsy.
    37. Omega Patents, LLC v. CalAmp Corp. United States District Court, Middle District of Florida, Case No. 6:13-cv-1950. Expert report and deposition. Evaluation of patent infringement including reasonable royalty related to vehicle tracker devices on automobiles.
    38. Tessera, Inc. v. UTAC (Taiwan) Corporation. United States District Court, Northern District of California, Case No. 5:10-cv-04435. Expert report, deposition, and declaration. Evaluation of breach of contract damages including lost royalties and prejudgment interest related to semiconductor packaging.
    39. nQueue, Inc. v. Control Systems (USA) Inc. United States District Court, Central District of California, Case No. 8:12-cv-01365-BPO-RNBx. Expert report. Evaluation of patent infringement including reasonable royalty related to expense tracking systems for multi-function copy devices.
    40. Kevin O’Halloran v. Harris Corporation and RPX Corporation. United States Bankruptcy Court, Middle District of Florida, Case No. 8:13-ap-00571. Expert report, deposition testimony, and trial testimony. Evaluation of patent valuation including patent portfolios, valuation, and valuation context related to telecommunications technologies.
    41. UCB, Inc. and UCB Manufacturing, Inc. v. Teva Pharmaceuticals USA, Inc. United States District Court, Northern District of Georgia, Case No. 12-cv-04420-CAP. Expert reports (x2), deposition testimony (x2), and hearing testimony. Evaluation of patent infringement including lost profits, reasonable royalty, and commercial success related to Metadate CD (methylphenidate hydrochloride) for the treatment of ADHD.
    42. In re: Victoria J. Wagner. United States Bankruptcy Court, Southern District of California, Case No. 13-06596-MM7. Expert declaration. Evaluation of labor and employment including analysis of expenditures, living standards, taxation.
    43. Invensas Corp. v. Renesas Electronics Corp. United States District Court, District of Delaware, Case No. 11-cv-00448-GMS. Expert report. Evaluation of patent infringement including reasonable royalty related to semiconductor packaging.
    44. In re Sanitec Industries, Inc, Debtor; Sanitec Industries, Inc. v. Micro-Waste Corp., et al. and related claims. United States District Court, Central District of California, Western Division, Case No. 09-cv-03488-PA. Expert report. Evaluation of breach of contract, false advertising, unfair competition, trademark infringement related to hospital microwave disinfection units.
    45. Aqua-Lung America, Inc. v. American Underwater Products, Inc., d/b/a Oceanic and Two Forty Deuce. United States District Court, Northern District of California, Case No. 5:07-cv-02346-RS. Expert report and deposition testimony. Evaluation of patent infringement and trade secret misappropriation including lost profits, reasonable royalty, and unjust enrichment related to scuba diving equipment.